Advench Pharmaceutical Private Limited

Olimab Injection is a medication primarily used for the treatment and prevention of osteoporosis in postmenopausal women and men at increased risk of fractures. It contains Denosumab, a monoclonal antibody that works by inhibiting a protein called RANK ligand (RANKL). This protein plays a crucial role in the formation and activity of osteoclasts—the cells responsible for bone resorption. By blocking RANKL, Denosumab reduces bone breakdown, increases bone mineral density, and lowers the risk of fractures. Olimab is typically administered as a subcutaneous injection of 60 mg once every six months by healthcare professionals, usually in the upper arm, thigh, or abdomen. This administration schedule supports long-lasting effects to strengthen bones and prevent fractures. The injection comes in a pre-filled syringe of 1 ml containing 60 mg of Denosumab. It should be stored refrigerated between 2°C to 8°C and protected from freezing and light to maintain potency. Common side effects include rash, musculoskeletal pain, nerve pain, constipation, headache, upper respiratory infections, and joint pain. Patients are advised to take adequate calcium and vitamin D supplements during treatment to support bone health. Use with caution in individuals with certain medical conditions, and administration should be supervised by healthcare professionals to monitor for any adverse reactions. Olimab is effective in managing osteoporosis by slowing bone loss and helping maintain bone strength, making it a valuable treatment for patients at high risk of fractures.

Bonmax PTH Injection is an advanced osteoporosis treatment developed by Zydus Lifesciences Ltd., containing Teriparatide, a recombinant form of human parathyroid hormone. It is indicated for postmenopausal women, men, and patients on long-term corticosteroid therapy who are at high risk of fractures. Each 3 ml prefilled cartridge delivers 750 mcg of Teriparatide, with a recommended daily dose of 20 mcg administered subcutaneously into the thigh or abdomen. Bonmax PTH works by stimulating osteoblasts, thereby promoting new bone formation, increasing bone mineral density, and reducing the risk of spinal and hip fractures. It is generally prescribed for a maximum duration of 24 months in a patient’s lifetime, under strict medical supervision. For optimal results, calcium and vitamin D supplementation is often recommended alongside therapy. The injection must be stored in refrigeration between 2 °C to 8 °C and should not be frozen. Common side effects may include mild injection-site pain, nausea, dizziness, muscle cramps, or transient increases in calcium levels, which are usually temporary. With proven efficacy and safety, Bonmax PTH is a trusted therapy for managing osteoporosis and protecting patients against debilitating fractures, helping improve mobility and quality of life.

Teriparatide Injection is a recombinant form of human parathyroid hormone (PTH 1-34) used in the treatment of osteoporosis. It is indicated for patients at high risk of fractures, including postmenopausal women and men with primary or hypogonadal osteoporosis, as well as individuals with osteoporosis associated with long-term glucocorticoid therapy.

Teriparatide works by stimulating osteoblastic activity, leading to new bone formation, increased bone mineral density, and improved bone strength. Unlike antiresorptive therapies, it acts as an anabolic agent that enhances bone remodeling and reduces the risk of vertebral and non-vertebral fractures. It is typically administered as a once-daily subcutaneous injection, commonly available in a prefilled pen or injection device for ease of use. The recommended dosage is 20 mcg per day, with treatment duration generally limited to a maximum of 24 months over a patient’s lifetime.

The injection should be stored under refrigerated conditions at 2°C to 8°C to maintain stability and effectiveness. It is important that the product is handled under proper cold chain conditions throughout storage and transportation.